Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 0.29
(-8.63%)
SEK 0.29
(-8.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.78 Million SEK | 43.89% |
| 2022 | -63.77 Million SEK | -19.13% |
| 2021 | -53.53 Million SEK | -4.07% |
| 2020 | -51.43 Million SEK | -115.74% |
| 2019 | -23.84 Million SEK | 12.68% |
| 2018 | -27.3 Million SEK | -127.28% |
| 2017 | -12.01 Million SEK | 17.43% |
| 2016 | -14.55 Million SEK | -160.15% |
| 2015 | -5.59 Million SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -12.41 Million SEK | -4.45% |
| 2024 Q1 | -11.88 Million SEK | -25.5% |
| 2023 Q2 | -10.11 Million SEK | -87.29% |
| 2023 Q3 | -10.8 Million SEK | -6.87% |
| 2023 FY | -35.78 Million SEK | 43.89% |
| 2023 Q4 | -9.47 Million SEK | 12.35% |
| 2023 Q1 | -5.39 Million SEK | 58.14% |
| 2022 Q2 | -16.73 Million SEK | 25.6% |
| 2022 Q1 | -22.48 Million SEK | 42.5% |
| 2022 Q4 | -12.89 Million SEK | 19.95% |
| 2022 FY | -63.77 Million SEK | -19.13% |
| 2022 Q3 | -16.11 Million SEK | 3.72% |
| 2021 Q3 | -15.2 Million SEK | 4.57% |
| 2021 Q2 | -15.93 Million SEK | -195.34% |
| 2021 Q4 | -39.1 Million SEK | -157.25% |
| 2021 FY | -53.53 Million SEK | -4.07% |
| 2021 Q1 | 16.7 Million SEK | 198.32% |
| 2020 Q3 | -13.3 Million SEK | -31.61% |
| 2020 FY | -51.43 Million SEK | -115.74% |
| 2020 Q4 | -16.99 Million SEK | -27.72% |
| 2020 Q2 | -10.11 Million SEK | 8.33% |
| 2020 Q1 | -11.02 Million SEK | -106.57% |
| 2019 Q3 | -7.16 Million SEK | 9.21% |
| 2019 Q2 | -7.89 Million SEK | -276.12% |
| 2019 Q1 | -2.09 Million SEK | 86.25% |
| 2019 FY | -23.84 Million SEK | 12.68% |
| 2019 Q4 | -5.33 Million SEK | 25.47% |
| 2018 Q1 | -3.84 Million SEK | 7.89% |
| 2018 FY | -27.3 Million SEK | -127.28% |
| 2018 Q3 | -3.7 Million SEK | 17.53% |
| 2018 Q2 | -4.49 Million SEK | -17.03% |
| 2018 Q4 | -15.26 Million SEK | -311.73% |
| 2017 Q2 | -3.46 Million SEK | -10.16% |
| 2017 Q4 | -4.17 Million SEK | -235.48% |
| 2017 Q3 | -1.24 Million SEK | 64.08% |
| 2017 FY | -12.01 Million SEK | 17.43% |
| 2017 Q1 | -3.14 Million SEK | -3.29% |
| 2016 Q3 | -3.21 Million SEK | 27.85% |
| 2016 FY | -14.55 Million SEK | -160.15% |
| 2016 Q4 | -3.04 Million SEK | 5.35% |
| 2016 Q1 | -3.84 Million SEK | -5.06% |
| 2016 Q2 | -4.45 Million SEK | -15.87% |
| 2015 Q1 | -233.5 Thousand SEK | 0.0% |
| 2015 Q2 | -467 Thousand SEK | -100.0% |
| 2015 Q3 | -1.5 Million SEK | -222.91% |
| 2015 Q4 | -3.65 Million SEK | -142.57% |
| 2015 FY | -5.59 Million SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -161.369% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 3.721% |
| BioGaia AB (publ) | 365.35 Million SEK | 109.794% |
| Enzymatica AB (publ) | -49.72 Million SEK | 28.041% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 19.79% |
| Gabather AB (publ) | -9.43 Million SEK | -279.188% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | -69.649% |
| Nanexa AB (publ) | -76.39 Million SEK | 53.161% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -132.288% |
| ODI Pharma AB | 355.97 Thousand SEK | 10152.504% |
| Orexo AB (publ) | -128.3 Million SEK | 72.109% |
| Probi AB (publ) | 16.81 Million SEK | 312.759% |
| Swedencare AB (publ) | 58.6 Million SEK | 161.065% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 101.485% |
| Toleranzia AB | -7.45 Million SEK | -379.743% |
| Vivesto AB | -367.03 Million SEK | 90.25% |